P7C3-A20 treatment one year after TBI in mice repairs the blood-brain barrier, arrests chronic neurodegeneration, and restores cognition

Chronic neurodegeneration in survivors of traumatic brain injury (TBI) is a major cause of morbidity, with no effective therapies to mitigate this progressive and debilitating form of nerve cell death. Here, we report that pharmacologic restoration of the blood-brain barrier (BBB), 12 mo after murin...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Proceedings of the National Academy of Sciences - PNAS Ročník 117; číslo 44; s. 27667
Hlavní autori:	Vázquez-Rosa, Edwin, Shin, Min-Kyoo, Dhar, Matasha, Chaubey, Kalyani, Cintrón-Pérez, Coral J, Tang, Xinmiao, Liao, Xudong, Miller, Emiko, Koh, Yeojung, Barker, Sarah, Franke, Kathryn, Crosby, Danyel R, Schroeder, Rachel, Emery, Josie, Yin, Terry C, Fujioka, Hisashi, Reynolds, James D, Harper, Matthew M, Jain, Mukesh K, Pieper, Andrew A
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 03.11.2020
Predmet:	Animals Behavior, Animal - drug effects Behavior, Animal - physiology Blood-Brain Barrier - cytology Blood-Brain Barrier - drug effects Blood-Brain Barrier - pathology Blood-Brain Barrier - ultrastructure Brain Injuries, Traumatic - complications Brain Injuries, Traumatic - drug therapy Brain Injuries, Traumatic - pathology Carbazoles - pharmacology Carbazoles - therapeutic use Cells, Cultured Chronic Disease - drug therapy Cognition - drug effects Cognition - physiology Disease Models, Animal Endothelial Cells Endothelium, Vascular - cytology Endothelium, Vascular - drug effects Endothelium, Vascular - pathology Humans Male Mice Microscopy, Electron Microvessels - cytology Neurodegenerative Diseases - drug therapy Neurodegenerative Diseases - etiology Neurodegenerative Diseases - pathology Neurodegenerative Diseases - physiopathology Neuroprotective Agents - pharmacology Neuroprotective Agents - therapeutic use Primary Cell Culture Survivors neurodegeneration traumatic brain injury blood–brain barrier inflammation neuroprotection
ISSN:	1091-6490, 1091-6490
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Chronic neurodegeneration in survivors of traumatic brain injury (TBI) is a major cause of morbidity, with no effective therapies to mitigate this progressive and debilitating form of nerve cell death. Here, we report that pharmacologic restoration of the blood-brain barrier (BBB), 12 mo after murine TBI, is associated with arrested axonal neurodegeneration and cognitive recovery, benefits that persisted for months after treatment cessation. Recovery was achieved by 30 d of once-daily administration of P7C3-A20, a compound that stabilizes cellular energy levels. Four months after P7C3-A20, electron microscopy revealed full repair of TBI-induced breaks in cortical and hippocampal BBB endothelium. Immunohistochemical staining identified additional benefits of P7C3-A20, including restoration of normal BBB endothelium length, increased brain capillary pericyte density, increased expression of BBB tight junction proteins, reduced brain infiltration of immunoglobulin, and attenuated neuroinflammation. These changes were accompanied by cessation of TBI-induced chronic axonal degeneration. Specificity for P7C3-A20 action on the endothelium was confirmed by protection of cultured human brain microvascular endothelial cells from hydrogen peroxide-induced cell death, as well as preservation of BBB integrity in mice after exposure to toxic levels of lipopolysaccharide. P7C3-A20 also protected mice from BBB degradation after acute TBI. Collectively, our results provide insights into the pathophysiologic mechanisms behind chronic neurodegeneration after TBI, along with a putative treatment strategy. Because TBI increases the risks of other forms of neurodegeneration involving BBB deterioration (e.g., Alzheimer's disease, Parkinson's disease, vascular dementia, chronic traumatic encephalopathy), P7C3-A20 may have widespread clinical utility in the setting of neurodegenerative conditions.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1091-6490 1091-6490
DOI:	10.1073/pnas.2010430117